Alector, Inc.
NASDAQ:ALEC
5.07 (USD) • At close October 29, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Alector, Inc. |
Symbool | ALEC |
Munteenheid | USD |
Prijs | 5.07 |
Beurswaarde | 493,417,977 |
Dividendpercentage | 0% |
52-weken bereik | 3.66 - 8.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Arnon Rosenthal Ph.D. |
Website | https://www.alector.com |
An error occurred while fetching data.
Over Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)